Clinical Trial Update: Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating donor-derived ex-vivo expanded natural killer cell infusions in pediatric and young adult patients with high-risk acute myeloi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Donor-derived ex-vivo expanded natural killer cell infusion (natural killer cell therapy)

Snippet

Sponsor: Michael Pulsipher | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: ENROLLING_BY_INVITATION